One & One Green Technologies stock soars 100% after IPO debut
WAYNE, Pa. – Teleflex Incorporated (NYSE: TFX), a global provider of medical technologies with a market capitalization of $6.4 billion and annual revenue of $3.05 billion, announced today the FDA 510(k) clearance of its AC3 Range™ Intra-Aortic Balloon Pump (IABP). According to InvestingPro analysis, the company appears undervalued at its current trading price of $138.19, with strong financial health metrics and a remarkable 49-year history of consistent dividend payments. The device, an extension of the AC3 Optimus™ IABP technology, is designed to offer continuous cardiac support for patients during various transport scenarios, including ambulance and aircraft.
The AC3 Range™ IABP features a user-friendly interface, proprietary algorithms for precise timing support, and is equipped with transport-specific enhancements such as a full-size helium tank, dual power options, and a reinforced handle with swivel wheels for mobility. This innovation aims to provide stable cardiac assistance to patients who require transfer from smaller hospitals to specialized shock centers.
Dr. Christopher Buller, MD, Medical Director at Teleflex, emphasized the importance of patient stabilization during transport, noting that the AC3 Range™ IABP addresses this critical need with its compatibility with common ground and air ambulance vehicles.
Roger Graham, President and General Manager of Teleflex Interventional, highlighted the company’s longstanding commitment to advancing intra-aortic balloon pumping technology over nearly four decades. He stated that with the AC3 Range™ IABP, Teleflex continues to serve patients throughout their care journey and support healthcare providers in the field.
The device is expected to be available for full market release in the United States and will start shipping to customers in the second quarter of 2025. Teleflex will also participate in the 45th Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) from April 27-30 in Boston, MA. At the event, Teleflex will host a lunch symposium on IABP therapy in cardiac transplant patients and showcase both the AC3 Optimus™ and AC3 Range™ IABPs at booth 623.
This news is based on a press release statement from Teleflex Incorporated. The company, known for its diverse portfolio of medical solutions, continues to focus on its mission to improve health and quality of life through innovative medical technologies. For a comprehensive analysis of Teleflex’s financial health, growth prospects, and additional insights, investors can access the detailed Pro Research Report available on InvestingPro, which covers over 1,400 top US stocks with expert analysis and actionable intelligence.
In other recent news, Teleflex Incorporated has reported preliminary results from its Ringer™ PBC study, which aims to manage coronary perforations during percutaneous coronary intervention procedures. The study showed that the device met its primary efficacy endpoint in 73.3% of participants, with successful device delivery in 86.7% of cases. Meanwhile, Teleflex is undergoing significant corporate changes, including the acquisition of BIOTRONIK’s Vascular Intervention business for approximately €760 million and a planned spin-off of its Acute Care, OEM, and Urology businesses. This restructuring is expected to decrease the company’s revenues and EBITDA by about 40% and 20%, respectively.
Moody’s has revised Teleflex’s outlook to negative, reflecting operational and execution risks associated with these transactions, although it affirmed the company’s Ba1 Corporate Family Rating. Needham has maintained a Hold rating on Teleflex, citing skepticism about growth rates for the newly formed entities post-spin-off. Truist Securities also reduced its price target for Teleflex to $149 from $200, maintaining a Hold rating due to uncertainties surrounding the company’s restructuring plans. Additionally, Teleflex has initiated a $300 million accelerated share repurchase program, funded through its existing credit facility, as part of a broader $500 million share repurchase plan.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.